| __timestamp | Eli Lilly and Company | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 6620800000 | 504755000 |
| Thursday, January 1, 2015 | 6533000000 | 838526000 |
| Friday, January 1, 2016 | 6452000000 | 1177697000 |
| Sunday, January 1, 2017 | 6588100000 | 1320433000 |
| Monday, January 1, 2018 | 5975100000 | 1556200000 |
| Tuesday, January 1, 2019 | 6213800000 | 1834800000 |
| Wednesday, January 1, 2020 | 6121200000 | 1346000000 |
| Friday, January 1, 2021 | 6431600000 | 1824900000 |
| Saturday, January 1, 2022 | 6440400000 | 2115900000 |
| Sunday, January 1, 2023 | 6941200000 | 2631300000 |
| Monday, January 1, 2024 | 8593800000 | 2954400000 |
Data in motion
In the competitive landscape of pharmaceuticals, understanding financial trends is crucial. Over the past decade, Eli Lilly and Company and Regeneron Pharmaceuticals, Inc. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Eli Lilly's SG&A expenses have seen a steady increase, peaking in 2023 with a 5% rise from the previous year. In contrast, Regeneron has experienced a more dramatic growth, with expenses surging by over 400% during the same period.
These trends highlight the differing strategies of these pharmaceutical giants, with Eli Lilly focusing on steady growth and Regeneron on rapid expansion.
Who Optimizes SG&A Costs Better? Eli Lilly and Company or Zoetis Inc.
Comparing SG&A Expenses: Eli Lilly and Company vs argenx SE Trends and Insights
Comparing SG&A Expenses: Eli Lilly and Company vs Halozyme Therapeutics, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and Amneal Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and Perrigo Company plc
Eli Lilly and Company and Wave Life Sciences Ltd.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and BioCryst Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Regeneron Pharmaceuticals, Inc. and Neurocrine Biosciences, Inc.
Operational Costs Compared: SG&A Analysis of Regeneron Pharmaceuticals, Inc. and Alpine Immune Sciences, Inc.
Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Grifols, S.A.
Regeneron Pharmaceuticals, Inc. vs PTC Therapeutics, Inc.: SG&A Expense Trends
Regeneron Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared